Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GNAI3 | P08754 | 8/20 | 0.38 |
| ▸ | GNAO1 | P09471 | 8/20 | 0.38 |
| ▸ | GNAI1 | P63096 | 8/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3107942 | 0.94 | GNAI3 (0.41) | KMT2AALDH1A1MAPTKDM4EGNAI3 | |
| SCHEMBL25253971 | 0.92 | GNAO1 (0.43) | KMT2AALDH1A1MAPTKDM4EGNAI3 | |
| SCHEMBL25420992 | 0.92 | GNAO1 (0.43) | KMT2AALDH1A1MAPTKDM4EGNAI3 | |
| SCHEMBL25420232 | 0.92 | GNAO1 (0.43) | KMT2AALDH1A1MAPTKDM4EGNAI3 | |
| SCHEMBL10464788 | 0.92 | GNAO1 (0.43) | KMT2AALDH1A1MAPTKDM4EGNAI3 | |
| Hydrochloric Acid SCHEMBL7529754 | 0.91 | GNAO1 (0.46) | KMT2AKDM4EGNAI3GNAO1GNAI1 | |
| SCHEMBL190917 | 0.88 | L3MBTL1 (0.45) | KMT2AALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL31711454 | 0.86 | L3MBTL1 (0.44) | KMT2AALDH1A1MAPTKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL999877 | 0.86 | L3MBTL1 (0.44) | KMT2AALDH1A1MAPTKDM4ENPC1 | |
| SCHEMBL734812 | 0.85 | L3MBTL1 (0.44) | ALDH1A1MAPTKDM4ENPC1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4441137-A1 | MELT ADDITIVES FOR LOW SURFACE-ENERGY APPLICATIONS | 3M Innovative Properties Company (US) | 2024-10-09 | — | — | EP | disclosed |
| EP-4402124-A1 | NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | Prosetta Biosciences, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | PROSETTA BIOSCIENCES, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240190826-A1 | Novel Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | PROSETTA BIOSCIENCES, INC. | 2024-06-13 | — | — | US | disclosed |
| WO-2023099977-A1 | MELT ADDITIVES FOR LOW SURFACE-ENERGY APPLICATIONS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230147603-A1 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | PROSETTA BIOSCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| WO-2023069770-A1 | NOVEL HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | PROSETTA BIOSCIENCES, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| US-8883781-B2 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| CN-101500575-A | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMA (US) | 2009-08-05 | — | — | CN | disclosed |
| EP-2043654-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2009-04-08 | — | — | EP | disclosed |
| WO-2007146284-A2 | THIENOPYRIMIDINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132111-A1 | Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | NCOR1, HAVCR2, NR3C1 | KMT2A 4124/4885ALDH1A1 3991/4885MAPT 3761/4885 |
| US-12017997-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | KMT2A 4108/4885ALDH1A1 4359/4885MAPT 3295/4885 |
| US-20240190826-A1 | Novel Host-Targeted Pan-Respiratory Antiviral Small Molecule Therapeutics | MAVS, SARS1, ZC3HAV1 | KMT2A 3926/4885ALDH1A1 4452/4885MAPT 3145/4885 |
| US-20070287717-A1 | Thienopyrimidines useful as modulators of ion channels | KCNJ1, KCNJ2, TRPV1 | KMT2A 2787/4885ALDH1A1 1670/4885MAPT 2226/4885 |
| US-12459901-B2 | Host-targeted pan-respiratory antiviral small molecule therapeutics | MAVS, SARS1, ZC3HAV1 | KMT2A 4108/4885ALDH1A1 4359/4885MAPT 3295/4885 |
| US-20230147603-A1 | HOST-TARGETED PAN-RESPIRATORY ANTIVIRAL SMALL MOLECULE THERAPEUTICS | MAVS, SARS1, ZC3HAV1 | KMT2A 4108/4885ALDH1A1 4359/4885MAPT 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.